Oncotarget

Research Papers:

Assessment of cholecystokinin 2 receptor (CCK2R) in neoplastic tissue

Jyoti Roy, Karson S. Putt, Domenico Coppola, Marino E. Leon, Farah K. Khalil, Barbara A. Centeno, Noel Clark, Valerie E. Stark, David L. Morse and Philip S. Low _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:14605-14615. https://doi.org/10.18632/oncotarget.7522

Metrics: PDF 2410 views  |   HTML 2718 views  |   ?  


Abstract

Jyoti Roy1,2, Karson S. Putt1, Domenico Coppola3, Marino E. Leon3, Farah K. Khalil3, Barbara A. Centeno3, Noel Clark4, Valerie E. Stark5, David L. Morse5, Philip S. Low1,2

1Center for Drug Discovery, Purdue University, West Lafayette IN 47907 USA

2Department of Chemistry, Purdue University, West Lafayette IN 47907 USA

3Department of Anatomic Pathology, H. Lee Moffitt Cancer Center, Tampa FL 33612 USA

4Tissue Core, H. Lee Moffitt Cancer Center, Tampa FL 33612 USA

5Department of Cancer Imaging and Metabolism, Imaging and Technology Center of Excellence, H. Lee Moffitt Cancer Center, Tampa FL 33612 USA

Correspondence to:

Philip S. Low, e-mail: [email protected]

Keywords: cholecystokinin 2 receptor, CCK2R, CCKBR, gastrin receptor

Received: October 21, 2015     Accepted: January 29, 2016     Published: February 20, 2016

ABSTRACT

The expression of cholecystokinin 2 receptor (CCK2R, CCKBR or gastrin receptor) has been reported on a diverse range of cancers such as colorectal, liver, lung, pancreatic, ovarian, stomach, thyroid and numerous neuroendocrine/carcinoid tumors. Some cancers of the colorectum, lung, pancreas and thyroid have been shown to overexpress CCK2R in relation to normal matched tissues of the same organ. This reported overexpression has led to the development of a number of CCK2R-ligand targeted imaging and therapeutic agents. However, no comprehensive study comparing the expression of CCK2R in multiple cancers to multiple normal tissues has been performed. Herein, we report the immunohistochemical analysis of cancer samples from gastrointestinal stromal tumor (GIST), hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma, and thyroid cancer against multiple normal tissue samples from esophagus, liver, lung, pancreas, stomach, spleen and thyroid. These results show that CCK2R expression is present in nearly all cancer and normal samples tested and that none of the cancer samples had expression that was statistically greater than that of all of the normal samples.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7522